Metastatic colorectal cancer: Current treatment and future options for improved survival medical approach - Present status

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 3, 2012, Pages 296-314

  Glimelius, Bengt ^a,b   Cavalli Björkman, Nina ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

advanced colorectal cancer; chemotherapy; palliation; targeted drugs

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DIHYDROXYPYRIMIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OTERACIL; OXALIPLATIN; PANITUMUMAB; PLACEBO; TEGAFUR; UNCLASSIFIED DRUG; URACIL;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DRUG TARGETING; HEALTH CARE COST; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FORECASTING; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84857187062     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.640828     Document Type: Review

References (153)

1. Ragnhammar P, Hafström LO, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001;40:282-308. (Pubitemid 32588124)
2. Glimelius B, Grönberg H, Järhult J, Wallgren A, Cavallinståhl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003;42:476-92. (Pubitemid 37193839)
3. Lambert PC, Dickman PW, Osterlund P, Andersson T, Sankila R, Glimelius B. Temporal trends in the proportioncured for cancer of the colon and rectum: a population-based study using data from the Finnish Cancer Registry. Int J Cancer 2007;121:2052-9. (Pubitemid 47463170)
4. Meulenbeld HJ, van Steenbergen LN, Janssen-Heijnen ML, Lemmens VE, Creemers GJ. Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004. Ann Oncol 2008;19:1600-4.
5. Lemmens VE, de Haan N, Rutten HJ, Martijn H, Loosveld OJ, Roumen RM, et al. Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992-2008. Clin Exp Metastasis 2011;28:283-90.
6. Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen MH, Wentzel-Larsen T, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 2009;115:4679-87.
7. Cavalli-Bjorkman N, Lambe M, Eaker S, Sandin F, Glimelius B. Differences according to educational level in the management and survival of colorectal cancer in Sweden. Eur J Cancer 2011;47:1398-406.
8. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000;321:531-5.
9. Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 2007;8:898-911. (Pubitemid 47488054)
10. Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008;12:iii-x; xi-162.
11. Ragnhammar P, Brorsson B, Nygren P, Glimelius B. A prospective study of the use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence. Acta Oncol 2001;40:391-411. (Pubitemid 32588130)
12. Allegra C, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol NJ, et al. End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol 2007;25: 3572-5. (Pubitemid 47372593)
13. Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public [see comments]. BMJ 1990;300:1458-60. (Pubitemid 20195333)
14. Consensus Statement. Cytostatic drug treatment in advanced cancer. Stockholm: MFR, Spri; 1990.
15. Norges Offentliga Utredningar. Omsorg og kunnskap (Care and knowledge). In Norwegian: Norsk Kreftplan; 1997; NOU 197:20.
16. Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM Jr, Blum D, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009;27:3868-74.
17. McCabe C, Bergmann L, Bosanquet N, Ellis M, Enzmann H, von Euler M, et al. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann Oncol 2009;20:403-12.
18. Glimelius B, Hoffman K, Graf W, Haglund U, Nyrén O, Påhlman L, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995;6: 267-74.
19. Iveson TJ, Hickish T, Schmitt C, Van Cutsem E. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer 1999;35:1796-804. (Pubitemid 29512311)
20. Cunningham D, Falk S, Jackson D. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. Br J Cancer 2002;86:1677-83. (Pubitemid 34712907)
21. Krol M, Koopman M, Uyl-de Groot C, Punt CJ. A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. Expert Opin Pharmacother 2007;8:1313-28. (Pubitemid 47034417)
22. National Institute for Health and Clinical Excellence. Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. 2009;118. www.nice.org.uk.
23. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994;16:1136-42. (Pubitemid 24118273)
24. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Sequential methotrexate/5-fluorouracil/leucovorin (MFL) is superior to 5-fluorouracil alone in advanced symptomatic colorectal carcinoma. A randomized trial. J Clin Oncol 1989; 7:1437-46.
25. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7:1407-18. (Pubitemid 19245110)
26. Cunningham D, Pyrhönen S, James RD, Pant CJA, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-18. (Pubitemid 28510874)
27. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992;10:904-11.
28. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306: 752-5. (Pubitemid 23080053)
29. Allen-Mersh TG, Earlam S. Fordy, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxouridine infusion for colorectal liver metastases. Lancet 1994;344:1255-60. (Pubitemid 24334681)
30. Funaioli C, Longobardi C, Martoni AA. The impact of chemotherapy on overall survival and quality of life of patients with metastatic colorectal cancer: a review of phase III trials. J Chemother 2008;20:14-27. (Pubitemid 351428657)
31. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 1993;4:235-41.
32. Glimelius B, Hoffman K, Olafsdottir M, Påhlman L, Sjödén P, Wennberg A. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma. A randomized comparison of two regimens. Eur J Cancer Clin Oncol 1989;25:829-35. (Pubitemid 19164327)
33. Glimelius B, Hoffman K, Graf W, Påhlman L, Sjödén P-O, Wennberg A. Quality of life during chemotherapy in symptomatic patients with advanced colorectal cancer. Cancer 1994;73:556-62. (Pubitemid 24046593)
34. Glimelius B, Graf W, Hoffman K, Pahlman L, Sjoden PO, Wennberg A. General condition of asymptomatic patients with advanced colorectal cancer receiving palliativechemotherapy. A longitudinal study. Acta Oncol 1992;31: 645-51. (Pubitemid 23023464)
35. Glimelius B, Jacobsen A, Graf W, Berglund Å, Gadeberg C, Hanse P, et al. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: A prospective randomized trial. Eur J Cancer 1998;34:674-8.
36. Jakobsen A, Berglund Å, Glimelius B, Froedin J-E, Hansen F, Kjaer M, et al. Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. Acta Oncol 2002;41:525-31. (Pubitemid 36061322)
37. Borner MM, Castiglione M, Bacchi M, Weber W, Herrmann R, Fey MF, et al. The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial. Ann Oncol 1998;9: 535-41. (Pubitemid 28270642)
38. Graf W, Glimelius B, Påhlman L, Bergström R. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 1994;70: 559-63. (Pubitemid 24268565)
39. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000;356:373-8. (Pubitemid 30487493)
40. Nygren P, Blomqvist L, Bergh J, Astrom G. Radiological assessment of tumour response to anti-cancer drugs: time to reappraise. Acta Oncol 2008;47:316-18.
41. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14. (Pubitemid 11167383)
42. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-9.
43. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
44. Suzuki C, Blomqvist L, Sundin A, Byström P BÅ, Glimelius B. The initial change in tumor size predicts response and survival in metastatic colorectal cancer patients treated with chemotherapy. Ann Oncol 2011; in press.
45. Caudry M, Bonnel C, Floquet A, Marsault C, Quetin P, Pujol J, et al. A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. Am J Clin Oncol 1995;18: 118-25.
46. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer - A tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997;15:368-81. (Pubitemid 27020595)
47. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106. (Pubitemid 33049527)
48. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704. (Pubitemid 41007824)
49. Pazdur R, Douillard J, Skillings J. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:abstract 1009.
50. Carmichel J, Popiela T, Radstone D. Randomised comparative study of ORZEL (Oral Uracil/Tegafur) (UFT) plus leucovorin (LV) versus parenteral 5-fluorouracil (5-FU) plus LV in patient with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:abstract 1015.
51. Wolmark N, Wieand S, Lembersky B, Colangelo L, Smith R, Pazdur R. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP Protocol C-06. Proc Am Soc Clin Oncol 2004;22: abstract 3508.
52. Yasui H, Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, et al. Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. Jpn J Clin Oncol 2009;39:315-20.
53. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-15. (Pubitemid 27074252)
54. Aranda E, Diaz-Rubio E, Cervantes A, Antón-Torres A, Carrato A, Massuti T, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-h continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol 1998;9:727-31. (Pubitemid 28394158)
55. Weh HJ, Zschaber R, Braumann D, Hoelzer P, Hoffmann R, Becker K, et al. A randomized phase III study comparing weekly folinic acid (FA) and high-dose 5-fluorouracil (5-FU) with monthly 5-FU/FA (days 1-5) in untreated patients with metastatic colorectal carcinoma. Onkologie 1998;21:403-7. (Pubitemid 28536434)
56. Vincent M, Ho C, Tomiak A, Winquist E, Whiston F, Stitt L. Toxicity analysis of the 5-day bolus 5-fluorouracil/ folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose. Clin Colorectal Cancer 2002;2:111-18.
57. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997;8:876-85. (Pubitemid 27487802)
58. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47. (Pubitemid 30644117)
59. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47. (Pubitemid 30036347)
60. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109-16.
61. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Mabro M, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5- fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001;37: 1000-5. (Pubitemid 32397685)
62. Martoni A, Mini E, Pinto C, Nobili S, Gentile AL, Dentico P, et al. Oxaliplatin and protracted continuous 5- fluorouracil infusion in patients with pretreated advanced colorectal carcinoma. Ann Oncol 2001;12:519-24. (Pubitemid 32472109)
63. Ravaioli A, Marangolo M, Pasquini E, Rossi A, Amadori D, Cruciani G, et al. Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol 2002;20:2545-50. (Pubitemid 34525742)
64. Sørbye H, Glimelius B, Berglund Å, Fokstuen T, Tveit KM, Braendengen M, et al. Multicentre phase II study of Nordic 5-fluorouracil/ Leucovorin bolus schedule combined with oxaliplatin (FLOX) as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004;22:31-8. (Pubitemid 41095111)
65. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008;26:5910-17.
66. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-12. (Pubitemid 28510873)
67. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7. (Pubitemid 30162806)
68. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
69. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801-7. (Pubitemid 32880058)
70. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006;24:3347-53. (Pubitemid 46638888)
71. Glimelius B, Ristamaki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit KM, et al. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 2002;13:1868-73. (Pubitemid 36040775)
72. Glimelius B, Sorbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit KM, et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (LV5FU2) in patients with metastatic colorectal cancer. Ann Oncol 2008;19:909-14. (Pubitemid 351627306)
73. Byström P, Johansson B, Bergström I, Berglund Å, Sorbye H, Tveit KM, et al. Health-related quality of life as therapeutic guidance in patients with advanced colorectal cancer receiving palliative combination chemotherapy. Manuscript. 2011.
74. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011;105:58-64.
75. Fuchs CS, Marshall J, Mitchell EP, Wierzbicki V, Ganju V, Jeffery M, et al. Updated results of BICC-C study comparing first-line irinotecan/ fluoropyrimidine combinations ± celecoib in mCRC: clinical data cut-off September 1, 2006. Proc ASCO 2007;abstract 276.
76. Kohne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, et al. Irinotecan combined with infusional 5- fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008; 19:920-6. (Pubitemid 351627308)
77. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomized controlled trial. Lancet 2007;370:135-42. (Pubitemid 47042893)
78. Ducreux M, Adenis A, Mendiboure J, Francois E, Boucher E, Chauffert B, et al. Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study). J Clin Oncol 2009; 27:abstract 4086.
79. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104-a randomized trial of the German AIO CRC study group. J Clin Oncol 2011;29:1050-8.
80. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37. (Pubitemid 41095086)
81. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11:38-47.
82. Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010;16:3133-43.
83. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-69. (Pubitemid 46606353)
84. Kim GP, Sargent DJ, Mahoney MR, Rowland KM Jr, Philip PA, Mitchell E, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 2009;27:2848-54.
85. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007;370: 143-52. (Pubitemid 47042894)
86. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009;14:862-70.
87. Hess GP, Wang PF, Quach D, Barber B, Zhao Z. Systemic Therapy for Metastatic Colorectal Cancer: patterns ofchemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract 2010;6:301-7.
88. Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011;377:1749-59.
89. Cunningham D, Sirohi B, Pluzanska A, Utracka-Hutka B, Zaluski J, Glynne-Jones R, et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 2009;20:244-50.
90. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-6. (Pubitemid 46797946)
91. Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst 2011;103:21-30.
92. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomized phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94:798-805.
93. Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008;62:195-201. (Pubitemid 351692073)
94. Morelli MF, Santomaggio A, Ricevuto E, Cannita K, De Galitiis F, Tudini M, et al. Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. Oncol Rep 2010;23:1635-40.
95. Zarate R, Rodriguez J, Bandres E, Patino-Garcia A, Ponz- Sarvise M, Viudez A, et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer 2010;102:987-94.
96. Vasile E, Masi G, Fornaro L, Cupini S, Loupakis F, Bursi S, et al. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the firstline treatment of metastatic colorectal cancer. Br J Cancer 2009;100:1720-4.
97. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. (Pubitemid 38702844)
98. Uyl-de Groot CA, Giaccone G. Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology? Curr Opin Oncol 2005;17:392-6. (Pubitemid 40904430)
99. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
100. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-705.
101. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-12.
102. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009;27:199-205.
103. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010;28:3191-8.
104. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009;20:1842-7.
105. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19.
106. Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX- 4) as second-line therapy in metastatic colorectal cancer: a randomized phase II noninferiority study. Ann Oncol 2008;19:1720-6.
107. Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumabcontaining chemotherapy. Br J Cancer 2011;104:599-604.
108. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011;60:116-29.
109. Van Cutsem E, Tabernero J, Lakomy R, Prausova J, Ruff P, Van Hazel G, et al. Intravenous (IV) Aflibercept versus placebo in combination with Irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): Results of a multinational phase III trial (EFC 10262-VELOUR). Ann Oncol 2011;22–Suppl 5): v-10-v8.abstract O-0024..
110. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10. (Pubitemid 46211358)
111. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus Irinotecan in Irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45. (Pubitemid 38944402)
112. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8. (Pubitemid 350106711)
113. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25: 1658-64. (Pubitemid 46797944)
114. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
115. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
116. Tejpar S, Bokemeyer C, Celik I, Schlichting M, Sartorius U, Van Cutsem E. Influence of KRAS G13D mutations on outcome in patiens with metastic colorectal cancer (mCRC) treated with first-line chemotherapy with or wityout cetuximab J Clin Oncol. 2011;29:abstract 3511.
117. Stintzing S, Neumann J, Jung A, Fischer von Weikersthal L, Decker T, Vehling Kaiser U, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306. J Clin Oncol 2011;29:abstract 3575.
118. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
119. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor kras and braf mutation status. J Clin Oncol 2011;29:2011-19.
120. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009;27:5931-7.
121. Tot T. Towards a renaissance of subgross breast morphology. Eur J Cancer 2010;46:1946-8.
122. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
123. Maughan T. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial. J Clin Oncol 2010;28:abstract 3502.
124. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Soerbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin and oxaliplatin (Nordic FLv) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The Nordic VII study. J Clin Oncol 2011, in press.
125. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28: 4697-705.
126. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706-13.
127. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563-72.
128. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-80.
129. Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007;25:4557-61. (Pubitemid 350035312)
130. Feliu Batlle J, Cuadrado E, Castro J, Caldes T, Belda C, Sastre J, et al. Irinotecan-cetuximab-bevacizumab as a salvage treatment in heavily pretreated metastatic colorectal cancer patients: a retrospective observational study. Chemotherapy 2011;57:138-44.
131. Larsen FO, Pfeiffer P, Nielsen D, Skougaard K, Qvortrup C, Vistisen K, et al. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer. Acta Oncol 2011;50:574-7.
132. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008;26: 4906-11.
133. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-16. (Pubitemid 351392040)
134. Papadimitriou CA, Papakostas P, Karina M, Malettou L, Dimopoulos MA, Pentheroudakis G, et al. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. BMC Med 2011;9:10.
135. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29:11-16.
136. Glimelius B, Lahn M, Gawande S, Cleverly A, Darstein C, Musib L, et al. A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer. Ann Oncol 2010;21:1020-6.
137. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006;24:394-400. (Pubitemid 46630458)
138. Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003; 361:457-64. (Pubitemid 36173710)
139. Lal R, Dickson J, Cunningham D, Chau I, Norman AR, Ross PJ, et al. A randomized trial comparing definedduration with continuous irinotecan until diseaseprogression in fluoropyrimidine an thymidylate synthase inhibitor-resistant advanced colorectal cancer. J Clin Oncol 2004;22:3023-31. (Pubitemid 41103713)
140. Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Nicolella D, et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomized 'GISCAD' trial. Ann Oncol 2011;22:1236-42.
141. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009;27: 5727-33.
142. Hochster HS. Stop and go: yes or no? J Clin Oncol 2009;27: 5677-9.
143. Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004; 15:1330-8. (Pubitemid 39302467)
144. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-9. (Pubitemid 29342371)
145. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001;8:347-53. (Pubitemid 32422861)
146. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644-57. discussion 57-8.
147. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009;20: 985-92.
148. NordlingerB,GuiguetM,Vaillant J,BalladurP,BoudjemaK, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. Cancer 1996;77:1254-62.
149. Asghar U, Hawkes E, Cunningham D. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer 2010;9: 274-81.
150. Papamichael D, Audisio R, Horiot JC, Glimelius B, Sastre J, Mitry E, et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 2009;20:5-16.
151. Blanke CD, Bot BM, Thomas DM, Bleyer A, Kohne CH, Seymour MT, et al. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. J Clin Oncol 2011;29:2781-6.
152. Stathopoulos GP, Batziou C, Trafalis D, Koutantos J, Batzios S, Stathopoulos J, et al. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 2010;78:376-81.
153. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25: 1539-44. (Pubitemid 46733080)